Erlotinib loaded pegylated polypeptide lipid nanocapsules to enhance the anticancer efficacy in non-small cell lung cancer

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: KIM, Jong Oh (Yeungnam University, Gyeongsan-si, Korea, Republic Of)
  • Co-author(s): Jae Hee Kim: Yeungnam University, Gyeongsan-si, Korea, Republic Of
    Jun Ho Son: Yeungnam University, Gyeongsan-si, Korea, Republic Of
    Myung-Ja Hong: Yeungnam University, Gyeongsan-si, Korea, Republic Of
    Young-Im Lee: Yeungnam University, Gyeongsan-si, Korea, Republic Of
    Dong Shik Kim: Hanyang University, Ansan-si, Korea, Republic Of
    Han-Gon Choi: Hanyang University, Ansan-si, Korea, Republic Of
    Chul Soon Yong: Yeungnam University, Gyeongsan-si, Korea, Republic Of
    Jong Oh Kim: Yeungnam University, Gyeongsan-si, Korea, Republic Of
  • Abstract:

    Background

    Lung cancer is the leading cause of cancer-related death worldwide. ERL blocks the kinase activity by selectively binding to the ATP-binding site of EGFR. The oral delivery of ERL is accompanied by severe side effects including rash, diarrhea, gastrointestinal (GI) perforations, ocular lesions, and hematological disorders. Therefore,..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login